<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01630252</url>
  </required_header>
  <id_info>
    <org_study_id>PGL11-021</org_study_id>
    <nct_id>NCT01630252</nct_id>
  </id_info>
  <brief_title>PGL5001 Proof of Concept Study in Inflammatory Endometriosis</brief_title>
  <acronym>JADE</acronym>
  <official_title>A Phase IIa Efficacy and Safety Study of PGL5001 Versus Placebo Administered for up to 5 Months With Concomitant Administration of Depot Medroxyprogesterone Acetate for the Treatment of Peritoneal and/or Ovarian Endometriosis With an Inflammatory Component.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PregLem SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PregLem SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, three-part (Part A1, Part A2 and Part B),Phase II study investigating
      the efficacy, safety, pharmacokinetics and pharmacodynamics of the JNK inhibitor PGL5001
      orally administered for up to 5 months with concomitant DMPA administration for the treatment
      of laparoscopically diagnosed inflammatory endometriosis. The part A1 is open-label, the
      parts A2 and B are double-blind.

      The target population will be women of reproductive age and suffering from newly diagnosed
      peritoneal and/or ovarian endometriosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to end of treatment in the number and percentage of red lesions (and/or inflammatory lesions), based on total number of red and black lesions.</measure>
    <time_frame>at week 8, week 20</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>Part A2 - Active Treatment arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PGL5001 for 8 weeks + one DMPA injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A2 - Placebo Treatment arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PGL5001 matching placebo for 8 weeks + one DMPA injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B - Active treatment arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PGL5001 for 20 weeks + two DMPA injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B - Placebo Treatment arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PGL5001 matching placebo for 20 weeks + two DMPA 150mg injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A1 - Active Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PGL5001 for 8 weeks + one unique DMPA 150 mg injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PGL5001</intervention_name>
    <description>PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection</description>
    <arm_group_label>Part A2 - Active Treatment arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>PGL5001 matching placebo (twice a day) for 8 weeks + one unique DMPA 150 mg injection</description>
    <arm_group_label>Part A2 - Placebo Treatment arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PGL5001</intervention_name>
    <description>PGL5001 320mg/day (160 mg twice a day) for 20 weeks + DMPA 150mg injection. Second DMPA injection between 85 to 89 days after first injection</description>
    <arm_group_label>Part B - Active treatment arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>PGL5001 matching placebo (twice a day) for 20 weeks + DMPA 150mg injection. Second DMPA injection between 85 to 89 days after first injection</description>
    <arm_group_label>Part B - Placebo Treatment arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PGL5001</intervention_name>
    <description>PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection</description>
    <arm_group_label>Part A1 - Active Treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The Subject must provide written informed consent prior to initiation of any study
             related procedures.

          -  The Subject must be an adult woman of reproductive age, aged from 18 and above.

          -  The Subject must be a newly diagnosed patient suffering from peritoneal and/or ovarian
             endometriosis with at least 15% of the endometriotic lesions observed at the study
             diagnostic laparoscopy being red inflammatory lesions and with a proven histological
             diagnosis.

          -  The Subject must consent to the scheduling of a second laparoscopy for surgical
             treatment at the study end.

          -  The Subject must have a history of pelvic pain for at least 3 months prior to the
             screening visit.

        Exclusion Criteria:

          -  The Subject is over 40 years old and has a FSH serum level during Day 2-4 of her cycle
             ≥ 21.5 mIU/ml.

          -  The Subject has a positive pregnancy test at baseline or is breast-feeding or planning
             a pregnancy during the course of the study.

          -  The Subject is known for having a cause of chronic abdominal/pelvic pain other than
             endometriosis (e.g. inflammatory bowel disease, fibromyalgia, interstitial cystitis).

          -  The Subject has a history of surgical treatment for endometriosis prior to the study
             diagnostic laparoscopy.

          -  The Subject is requiring urgent surgical excision of endometriotic lesions at the time
             of first diagnostic laparoscopy.

          -  The Subject has a history (in the past 12 months) of or a current medical treatment
             for endometriosis other than NSAID (e.g. GnRH agonist or antagonist, danazol,
             continuous oral combined oestroprogestogens).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elke Bestel, MD</last_name>
    <role>Study Director</role>
    <affiliation>PregLem SA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prywatna Klinika Połozniczo-Ginekologiczna Sp z o.o.</name>
      <address>
        <city>Bialystok</city>
        <zip>15-224</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2012</study_first_submitted>
  <study_first_submitted_qc>June 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2012</study_first_posted>
  <last_update_submitted>June 2, 2014</last_update_submitted>
  <last_update_submitted_qc>June 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

